Additionally, the MDM2 proto-oncogene (MDM2) rs2279744 influenced prostate cancer risk and survival across different subtypes of tumor protein P53 rs1042522 carriers, whereas MDM2 rs2279744 alone did not have a significant association with prostate cancer outcomes [15–17]. This evidence concerns the gene TP53 and prostate carcinoma.